Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors.
Fazio
Nicola
N
Oberg
Kjell
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000556:secondary; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010456:Peptides, Cyclic / Q000008:administration & dosage; D011379:Prognosis; D011994:Recombinant Proteins; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010456:Peptides, Cyclic; D011994:Recombinant Proteins; C060347:lanreotide; D013004:Somatostatin